Curated News
By: NewsRamp Editorial Staff
August 23, 2024
New ALS Treatment Shows Positive Results in Clinical Trials
Discuss on Reddit
Discuss on SubstackTLDR
- Clene's CNM-Au8 showed significant improvement in key biomarkers among ALS patients, potentially giving them a treatment advantage.
- The biomarker and efficacy data was submitted to the FDA for accelerated approval, targeting a Type C meeting request.
- CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, offering hope for earlier patient benefit.
- Clene's latest updates and findings were presented at the Canaccord Genuity 44th Annual Growth Conference.
Impact - Why it Matters
This news matters as it represents a potential breakthrough in the treatment of ALS, offering hope to patients and their families. The positive results and potential accelerated approval pathway could mean faster access to a new treatment option for those suffering from this devastating disease.
Summary
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, announced positive results of two Phase 2 clinical trials of CNM-Au8 for the treatment of ALS. The trials showed significant improvement in key biomarkers, leading to a Type C meeting request with the FDA for an accelerated approval pathway. CEO Rob Etherington expressed optimism about CNM-Au8’s potential as a new ALS treatment.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, New ALS Treatment Shows Positive Results in Clinical Trials
